Co-Founder & CEO
Dr. Willem De Weerd, through his scientific education and extensive experience in the pharma industry, he is uniquely qualified to lead JNL Biopharmaceutics through the entire lifecycle—from initial drug design and early research to the creation of viable development pipelines. Dr. De Weerd brings scientific innovation while enabling commercial viability.
JNL Biopharmaceutics forms this unique blend of deep technical understanding and business insights. Practical experience dictates that leaders are not just managers, but they secure funding, manage complex pathways, while building a culture of innovation. With advanced scientific expertise and practical experience in the filed of biopharmaceuticals, Dr. de Weerd is well equipped to drive success of JNL Biopharmaceutics.
Having been engaged between USA and Europe, Dr. de Weerd is a prominent expert in the biologics, who leverages a unique dual-region background. His specialized education and cross-continental experience allow him to seamlessly guide JNL Biopharmaceutics through the entire lifecycle.
At Merck Serono S.A. (Switzerland), Dr. de Weerd's guidance was instrumental in bringing various biologics and biosimilars to the global stage.
While at Kenyon & Kenyon in New York, Dr. de Weerd acted as counsel for a variety of pharmaceutical firms, assisting them in navigating the legal landscapes and the regulatory pathways to successfully launch their products in this critical market.
- Drs in Chemistry / Utrecht University (NL)
- PhD in Biochemistry & Molecular Biology / University of Texas (USA)
- Juris Doctor (Law) / University George Washington University (USA)